Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Celgene survives Alvogen's attempt for inter partes review of Revlimid patent in US

firstwordpharmaMarch 15, 2019

Tag: Celgene , Alvogen , Revlimid patent

PharmaSources Customer Service